Search

everythinglearnresearchcommunity

for

Search:↓

Ruxolitinib helped a patient with alopecia areata regrow hair.

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Baricitinib is effective as a treatment for severe hair loss.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Upadacitinib effectively treats severe alopecia areata and is safe.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Ruxolitinib cream may help treat severe hair loss in children.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

A new compound shows promise as a topical treatment for hair loss.

JAK inhibitors might help treat alopecia areata.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Baricitinib is effective for severe alopecia areata but has some side effects.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.